Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-04. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized selank is normally supplied as a dry powder and is considered stable for extended periods when kept cold and dry. Moisture uptake is the main practical threat, because absorbed water promotes both hydrolysis and aggregation in the solid state. Vials are usually warmed to room temperature before opening so that condensation does not form on the powder. Supplier documentation commonly specifies -20 °C for routine storage, with -80 °C used for material intended to be archived for years.
Once dissolved, the peptide is markedly less stable than the dry powder. Aqueous solutions are subject to backbone hydrolysis and to microbial growth when they are handled without sterile technique. Buffered solutions near neutral pH are common for short-term laboratory work, while acidic conditions are sometimes used to improve solubility. Analytical laboratories generally prepare working solutions fresh rather than storing them, and a residual water film left in a reopened vial can seed degradation even when the container appears dry.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
| Property | Value | Notes |
|---|---|---|
| Typical purity specification | 95 percent or higher by RP-HPLC | Area percentage of the main peak |
| Identity confirmation | Electrospray ionization mass spectrometry | Observed mass compared with the theoretical value near 751.9 Da |
| Recommended dry storage | -20 °C, desiccated | -80 °C for multi-year archival material |
| Solution handling | Prepare fresh; avoid long storage | Sterile filtration reduces microbial load |
| Common synonyms | TKPRPGP; TP-7 | Sequence code and laboratory designation used interchangeably |
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
Peptide bonds are vulnerable to protease attack, and Selank is no exception. Measured half-life in serum is short, on the order of minutes in several reports, which explains why intranasal administration is the common route described in the literature. Absorption across the nasal mucosa partially bypasses first-pass hepatic metabolism. Quantitative data on human bioavailability remain limited and are difficult to compare across studies.
According to Druze tradition, Jesus sought sanctuary on this summit and held a clandestine meeting with his disciples there. Druze believe that Hamza ibn Ali was a reincarnation of Jesus, and that Hamza ibn Ali is the true Messiah, who directed the deeds of the Messiah Jesus "the son of Joseph and Mary", but when Jesus "the son of Joseph and Mary" strayed from the path of the true Messiah, Hamza filled the hearts of the Jews with hatred for him – and for that reason, they crucified him, according to the Druze manuscripts. Despite this, Hamza ibn Ali took him down from the cross and allowed him to return to his family, to prepare men for the preaching of his religion. In an epistle ascribed to one of the founders of Druzism, Baha al-Din al-Muqtana, probably written sometime between AD 1027 and AD 1042, accused the Jews of crucifying Jesus. The Druze believe that each spokesmen or prophets (natiq) has a "foundation" or "guardian" who is responsible for the esoteric, interpretative law, while the spokesmen or prophets (natiq) himself presents the apparent, obligatory law. According to Druze belief, Jesus, son of Joseph and Mary, the first limit and fifth spokesman or prophet natiq, appeared and replaced Moses' law with his own, proclaiming his message and appointing Simon Peter (Sham'un al-Safa) as his foundation. He had twelve apostles who called people to worship and unify the God and to obey Jesus, considered the son of the God the Father. However, his followers did not fully understand his words and symbols.
== Bibliography == Cynthia Zaferatos (2008). "The History Of Olive Oil" (PDF). EUROMED Sustainable Connections Policy Analysis. Anna Lindh Foundation. p. 2. Archived from the original (PDF) on 2012-04-07. Retrieved 2011-10-01 – via Western Washington University. Nayak, Shivananda; Nalabothu, Poorna; Sandiford, Steve; Bhogadi, Vidyasagar; Adogwa, Andrew (2006). "Evaluation of wound healing activity of Allamanda cathartica. L. And Laurus nobilis. L. Extracts on rats". BMC Complementary and Alternative Medicine. 6: 12. doi:10.1186/1472-6882-6-12. PMC 1456996. PMID 16597335.
The United States-India Science & Technology Endowment Fund is a joint fund established between the United States and India for the purpose of promoting innovation through science and technology. It is governed by a board representing both India and the United States and provides grants of up to $500,000 for joint projects between the U.S. and India.
Sources: en.wikipedia.org
=== Xander Lindt === Xander Lindt (Gustav Lindh) is a cocky young heir of the Lindt chocolate empire, and a member of Henry's entourage. He repeatedly demeans Yasmin after she rejects his sexual advances at a Swiss climate conference.
Containers with hard spouts date to early in recorded time, as evidence by archeological finds (see image). The first vessels known to be used for feeding infants had an opening at one end for filling the bottle, and a second at the other to be put into the baby's mouth. Examination of the organic residues on ancient ceramic baby bottles shows that they were used as early as 1200 BCE to feed babies with animal milk. Around 250 BCE to 300 BCE the Egyptians developed the ability to blow glass and the Romans blew clear feeding bottles of glass, but these did not obtain long-term popularity. Leather and wood were also used. By the 1700s infant-feeding vessels such as the feeding-cups, bubby-pots, and sucking-pots were also being made from materials that included pewter, tin, and silver.
== Symptoms == In AOA1, patients usually experience oculomotor apraxia, problems with innitiation (oculocephalic dissociation) and slowing of saccades, nystagmus, failure of fixation, excessive blinking, ataxia, tremor, neuropathy (which leads to hyporeflexia, diminished sense of vibration, and limb weakness), atrophy of the cerebellum, decreased levels of albumin and elevated levels of cholesterol, dysarthric speech, chorea (which might disappear as disease progresses). Occasionally, patients experience scoliosis, intellectual disability, dystonia, head thrust, elevated levels of creatine kinase and alpha-fetoprotein. Rarely, patients experience parkinsonism, myoclonic jerks, and pyramidal signs. Oculomotor apraxia, head thrust, and oculocephalic dissociation might be associated with much severe form of this disorder. Patients can experience subtle immune abnormalities such as lymphopenia of B- and T- cells (CD4+ and CD8+ T cells are affected), decreased levels of antibodies, low levels of T-cell receptor rearrangement excision circles and immunoglobulin κappa-deleting recombination excision circles, and lymphocytes are mildy sensetive to ionizing radiation.
While constitutional law concerns the European Union's governance structure, administrative law binds EU institutions and member state governments to follow the law. Both member states and the Commission have a general legal right or "standing" (locus standi) to bring claims against EU institutions and other member states for breach of the treaties. From the EU's foundation, the Court of Justice also held that the Treaties allowed citizens or corporations to bring claims against EU and member state institutions for violation of the Treaties and Regulations, if they were properly interpreted as creating rights and obligations. However, under Directives, citizens or corporations were said in 1986 to not be allowed to bring claims against other non-state parties. This meant courts of member states were not bound to apply a Union law where a State law conflicted, even though the member state government could be sued, if it would impose an obligation on another citizen or corporation. These rules on "direct effect" limit the extent to which member state courts are bound to administer EU law. All actions by EU institutions can be subject to judicial review, and judged by standards of proportionality, particularly where general principles of law, or fundamental rights are engaged. The remedy for a claimant where there has been a breach of the law is often monetary damages, but courts can also require specific performance or will grant an injunction, in order to ensure the law is effective as possible.
Sources: en.wikipedia.org
Sealed, desiccated storage at -20 °C or colder is the standard recommendation for research-grade material. Vials should reach room temperature before they are opened, which limits condensation. Repeated temperature cycling is discouraged.
A reported purity value reflects the share of the main peak in one chromatographic run and says nothing about identity. Confirming that the expected sequence is present requires a separate measurement such as mass spectrometry. Purity and identity are distinct questions.
A mass spectrum reports the molecular masses present in a sample and shows whether they match the value expected for selank, near 751.9 Da. It also flags common artifacts such as truncation or adduct formation. It does not establish correct stereochemistry or complete sequence order on its own.
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.